Population	Number of subjects	Age (years)	dp-ucMGP (pmol/L)	Reference
Diabetes type 2	198	mean 64; SD ± 8	mean 627; SD ± 451	Liaboeuf, S. et al. *Cardiovasc Diabetol* 13 (2014) 1-8
Diabetes type 2	66	mean 62; SD ± 12	mean 624; SD ± 638	Sardana, M. et al. *Am J Hypertens* 30 (2017) 196-201
Diabetes type 2	198	mean 64; SD ± 8.4	mean 626; SD ± 451	Jeannin, A.C. *PLOS One* 15 (2020) e0229145
Hypertension	99	mean 64; SD ± 10	mean 763; SD ± 854	Chirinos, J.A. et al. *J Am Soc Hypertens* 12 (2018) 681-689
Coronary Heart Disease	482	mean 62.6; SD ± 8.6	mean 803; SD ± 560	Mayer, O. et al. *Atherosclerosis* 235 (2014) 162-168
Stroke	317	mean 69.0; SD ± 8.9	mean 944; SD ± 674	
COPD	192	mean 61.9; SD ± 7.1	median 650; range 601-703	Piscaer, I. et al. *J Clin Med* 8 (2019) 1116
Chronic kidney disease	107	mean 67; SD ± 13	mean 1100; SD ± 713	Schurgers, L.J. et al. *Clin J Am Soc Nephrol* 5 (2010) 568-575
Chronic kidney disease	42	mean 58; SD ± 3	median 860; range 467-1190	Kurnatowska, I et al. *Pol Arch Med Wedwn* 125 (2015) 631-640
Chronic kidney disease	38	mean 58.6; SD ± 11.2	mean 1018.6; SD ± 498.3	Kurnatowska, I et al. *Kidney Blood Press Res* 41 (2016) 231-239
End-stage renal disease	97	mean 45; SD ± 14	median 1856; range 1194-3428	Meuwese, C.L. et al. *PLOS One* 10 (2015) e132353
Haemodialysis	188	mean 59; SD ± 11	mean 2850; SD ± 1768	Schlieper, G. et al. *J Am Soc Nephrol* 22 (2011) 387-395
Haemodialysis	40	mean 62; SD ± 16	mean 1868; SD ± 870	Cranenburg, E.C.M. e al. *Kidney Int* 82 (2012) 605-610
Haemodialysis	59	median 72.2; range 38-92	median 2872; range 123-7539	Caluwé, R et al. *Nephrol Dial Transpl* 29 (2014) 1385-1390
	53	median 69.1; range 24-93	median 2783; range 500-7567	
	53	median 71.2; range 29-92	median 3205; range 857-7813	
Haemodialysis	50	median 64.3; range 30-88	median 3175; range 954-7481	Westenfeld, R et al. *Am J Kidney Dis* 59 (2012) 186-195
Haemodialysis	37	mean 47.7; SD ± 10.4	mean 2139; SD ± 1102	Fain, M.E. et al. *Am J Hypertens* 31 (2018) 735–741
Haemodialysis	35	mean 70.8; SD ± 12.5	median 2906; range 815-5737	Uhlin, F. et al. *Scand J Clin Lab Invest* 79 (2019) 174-181
Haemodialysis plus calcifylaxis	20	mean 58; SD ±4	mean 3076; SD ± 289	Nigwekar, S.U. et al. *J Am Soc Nephrol* 28 (2017) 1717-1722
Haemodialysis without calcifylaxis	20	mean 62; SD ± 3	mean 1485; SD ± 436	
Kidney transplant	518	mean 51.3; SD ± 12.1	median 1038; range 733-1536	Keyzer, C.A. et al. *Am J Kidney Dis* 65 (2015) 474-483
Kidney transplant	60	median 56; range 48-63	median 753; range 543-1091	Boxma, P.Y. et al. *PLOS One* 7 (2012) e47991
Healthy controls	184	mean 60.8; SD ± 7.7	median 472; range 433-513	
COVID-19 'good outcome'	74	mean 63.7; SD ± 12.8 median 65.6; range 31.0-90.1	mean 1337; SD ± 992 median 1986; range 556-7599	
COVID-19 'poor outcome'	60	mean 72.3; SD ± 9.69 median 74.4; range 46.2-88.2	mean 2499; SD ± 2086 median 1694; range 595-11067	

Supplementary table 1: dp-ucMGP measurements in cohorts of diabetes, cardiovascular disease, COPD and renal disease corhorts compared to COVID-19 patients (n=134) and healthy controles used in the current study. 1: women only; 2: white South Africans; 3: black South Africans

Population	Number of subjects	Age (years)	dp-ucMGP (pmol/L)	Reference
General population or healthy controls	75	mean 53; SD ± 17	mean 447; SD ± 188	Cranenburg, E.C.M. et al. *Thromb Haemostas* 104 (2010) 811-822
	438	mean 68; range 60-80	mean 466; SD ± 277	Shea, M.K. et al. *J Nutr* 141 (2011) 1529-1534
	98	mean 58; SD ± 15	mean 442; SD ± 242	Schlieper, G. et al. *J Am Soc Nephrol* 22 (2011) 387-395
	42	mean 28; SD ± 7	mean 429; SD ± 140	Theuwissen, E. et al. *Brit J Nutr* 108 (2012) 1652-1657
	20	mean 59.2; SD ± 2.7	mean 448; SD ±167	Dalmeijer, G.W. et al. *Atherosclerosis* 225 (2012) 397-402
	22	mean 59.5; SD ± 3.0	mean 401; SD ± 131	
	18	mean 59.8; SD ± 3.3	mean 391; SD ± 118	
	518	mean 58.1; SD ± 7.1	mean 217; SD ± 210	Dalmeijer, G.W. et al. *Diabetes Care* 36 (2013) 3766-3771
	15	mean 29; SD ± 8	mean 361; SD ± 127	Theuwissen, E. et al. *Thromb Haemostas* 11 (2013) 1085-1092
	200 [1]	mean 66.9; SD ± 5.5	median 579; range 102-2952	Dalmeijer, G.W. et al. *J Nutr Biochem* 24 (2013) 624-628
	53	median 60.5; range 35-77	median 454; range 142-1612	Westenfeld, R et al. *Am J Kidney Dis* 59 (2012) 186-195
	1406	mean 49.5; SD ± 11.8	mean 167; SD ± 98	Dalmeijer, G.W. et al. *J Thromb Haemostas* 12 (2014) 1028-1034
	577	mean 59.9; SD ± 2.9	median 335; range 229-457	Van den Heuvel, E. et al. *Maturitas* 77 (2014) 137-141
	56	mean 56; SD ± 5	mean 442; SD ± 187	Knapen, M.H.J. et al. *J Nutr Scie* 4 (2015) e35, 1 - 8
	758	mean 63.3; SD ± 9.0	mean 299.6; SD ± 344.8	Dam, V. et al. J. Clin Endocrinol Metab 100 (2015) 2472-2479
	1001	mean 46; SD ± 17.2	mean 430; SD ± 200	Pivin, E. et al. *Hypertension* 66 (2015) 85-92
	244 [1]	mean 59.5; SD ± 3.3	mean 525; SD ± 266	Knapen, M.H.J. et al. *Thromb Haemostas* 113 (2015) 1135-1144
	791	mean 74; SD ± 5	mean 408	Shea, M.K. et al. *Osteoarthrit Cartilage* 23 (2015) 370-378
	2318	mean 43.5; SD ± 17.6	mean 340	Liu, Y.P. et al. *Hypertension* 65 (2015) 463-470
	1088	mean 74.6; SD ± 2.9	mean 417	Shea, M.K. et al. *J Gerontol Med Sci* 71 (2016) 1348-1355
	1087	mean 54.8; SD ± 13.0	mean 570.5; SD ± 330.8	Mayer, O. et al. *J Hum Hypertens* 30 (2016) 418-423
	362 [2]	mean 40.3; SD ± 12.9	median 693; range 563-935	Wei, F.F. et al. *E-Biomedicine* 4 (2016) 162-169
	352 [3]	mean 40.9; SD ± 11.5	median 338; range 220-693	
	80	mean 76.5; SD ± 4.6	mean 806; SD ± 361	Fulton, R.L. et al. *J Nutr Health Aging* 20 (2016) 325-233
	4275	mean 53; SD ± 12	median 372; range 221-552	Riphagen, I.J. et al. *Nutrients* 9 (2017) 1334
	37	mean 47.7; SD ± 7.4	mean 382; SD ± 181	Fain, M.E. et al. *Am J Hypertens* 31 (2018) 735–741
Healthy controls	184	mean 60.8; SD ± 7.7	median 472; range 433-513	
COVID-19 'good outcome'	74	mean 63.7; SD ± 12.8 median 65.6; range 31.0-90.1	mean 1337; SD ± 992 median 1986; range 556-7599	
COVID-19 'poor outcome'	60	mean 72.3; SD ± 9.69 median 74.4; range 46.2-88.2	mean 2499; SD ± 2086 median 1694; range 595-11067	

Supplementary table 2: dp-ucMGP measurements in cohorts of healthy controls from the general population compared to COVID-19 patients (n=134) and healthy controles used in the current study. 1: women only; 2: white South Africans; 3: black South Africans